VitaNova Life Sciences (VNOV) Accumulated Expenses (2017 - 2026)

VitaNova Life Sciences (VNOV) has 9 years of Accumulated Expenses data on file, last reported at $78959.0 in Q2 2026.

• Quarterly Accumulated Expenses rose 29.69% year-over-year to $78959.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $78959.0 (up 29.69% YoY) and the FY2026 annual result came in at $78959.0, up 29.69% from the prior year.
• Accumulated Expenses fell to $78959.0 in Q2 2026, from $81951.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $81951.0 in Q1 2026 to a low of $38391.0 in Q1 2022.
• A 5-year average of $56254.5 and a median of $50707.0 in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 61.02% — and 2023, when it slipped 4.94%.
• Tracing VNOV's Accumulated Expenses over 5 years: stood at $53343.0 in 2022, then slipped by 4.94% to $50707.0 in 2023, then slipped by 1.0% to $50202.0 in 2024, then soared by 36.87% to $68713.0 in 2025, then grew by 14.91% to $78959.0 in 2026.
• The last three Accumulated Expenses figures came in at $78959.0 (Q2 2026), $81951.0 (Q1 2026), and $68713.0 (Q4 2025), per Business Quant data.